MXPA04004355A - Tratamiento de combinacion que comprende zd6474 y un taxano. - Google Patents
Tratamiento de combinacion que comprende zd6474 y un taxano.Info
- Publication number
- MXPA04004355A MXPA04004355A MXPA04004355A MXPA04004355A MXPA04004355A MX PA04004355 A MXPA04004355 A MX PA04004355A MX PA04004355 A MXPA04004355 A MX PA04004355A MX PA04004355 A MXPA04004355 A MX PA04004355A MX PA04004355 A MXPA04004355 A MX PA04004355A
- Authority
- MX
- Mexico
- Prior art keywords
- taxane
- human
- combination therapy
- antiangiogenic
- warm
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title abstract 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract 6
- 238000002648 combination therapy Methods 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000001603 reducing effect Effects 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0126879.6A GB0126879D0 (en) | 2001-11-08 | 2001-11-08 | Combination therapy |
| PCT/GB2002/005021 WO2003039551A1 (en) | 2001-11-08 | 2002-11-06 | Combination therapy comprising zd6474 and a taxane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04004355A true MXPA04004355A (es) | 2004-08-11 |
Family
ID=9925430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04004355A MXPA04004355A (es) | 2001-11-08 | 2002-11-06 | Tratamiento de combinacion que comprende zd6474 y un taxano. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050043395A1 (https=) |
| EP (1) | EP1446124B1 (https=) |
| JP (1) | JP4694127B2 (https=) |
| KR (1) | KR100959607B1 (https=) |
| CN (1) | CN1298328C (https=) |
| AR (1) | AR037346A1 (https=) |
| AT (1) | ATE335488T1 (https=) |
| AU (1) | AU2002337382B2 (https=) |
| BR (1) | BR0213906A (https=) |
| CA (1) | CA2464758C (https=) |
| CY (1) | CY1106259T1 (https=) |
| DE (1) | DE60213845T2 (https=) |
| DK (1) | DK1446124T3 (https=) |
| ES (1) | ES2269769T3 (https=) |
| GB (1) | GB0126879D0 (https=) |
| IL (2) | IL161744A0 (https=) |
| MX (1) | MXPA04004355A (https=) |
| NO (1) | NO328048B1 (https=) |
| NZ (1) | NZ532525A (https=) |
| PT (1) | PT1446124E (https=) |
| WO (1) | WO2003039551A1 (https=) |
| ZA (1) | ZA200403455B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100881105B1 (ko) * | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| ES2267748T3 (es) | 2000-04-07 | 2007-03-16 | Astrazeneca Ab | Compuestos de quinazolina. |
| SI1474420T1 (sl) * | 2002-02-01 | 2012-06-29 | Astrazeneca Ab | Spojine kinazolina |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| AU2003278383B2 (en) | 2002-11-04 | 2007-06-14 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
| KR20050100683A (ko) * | 2003-02-13 | 2005-10-19 | 아스트라제네카 아베 | 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| EP1648465B1 (en) * | 2003-07-10 | 2010-08-25 | AstraZeneca AB | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| AU2004291037A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0411378D0 (en) * | 2004-05-21 | 2004-06-23 | Astrazeneca Ab | Pharmaceutical compositions |
| WO2006002422A2 (en) * | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| PL1971338T3 (pl) * | 2005-12-22 | 2011-07-29 | Astrazeneca Ab | Połączenie ZD6474 i premetreksedu |
| EP2094268A2 (en) * | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| JP5739802B2 (ja) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩 |
| WO2010061208A2 (en) * | 2008-11-03 | 2010-06-03 | Astrazeneca Ab | Therapeutic treatment 555 |
| CN106478598B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种凡德他尼水合物晶体及其制备方法 |
| CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
| JP7737455B2 (ja) * | 2020-12-22 | 2025-09-10 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｓｏｓ１阻害剤としての新規キナゾリン誘導体化合物及びその用途｛ｎｏｖｅｌ ｑｕｉｎａｚｏｌｉｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｓ ｓｏｓ１ ｉｎｈｉｂｉｔｏｒｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝ |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| PT910382E (pt) * | 1996-04-26 | 2003-10-31 | Genaera Corp | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9727524D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| MXPA01008699A (es) * | 1999-02-24 | 2002-06-21 | Uab Research Foundation | Derivados de taxano para terapia de cancer dirigida. . |
| US6342219B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| KR100881105B1 (ko) * | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| AU2003249000B2 (en) * | 2002-08-09 | 2007-04-05 | Astrazeneca Ab | Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| KR20050100683A (ko) * | 2003-02-13 | 2005-10-19 | 아스트라제네카 아베 | 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법 |
| EP1648465B1 (en) * | 2003-07-10 | 2010-08-25 | AstraZeneca AB | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| PL1971338T3 (pl) * | 2005-12-22 | 2011-07-29 | Astrazeneca Ab | Połączenie ZD6474 i premetreksedu |
| WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
-
2001
- 2001-11-08 GB GBGB0126879.6A patent/GB0126879D0/en not_active Ceased
-
2002
- 2002-11-06 WO PCT/GB2002/005021 patent/WO2003039551A1/en not_active Ceased
- 2002-11-06 EP EP02772624A patent/EP1446124B1/en not_active Expired - Lifetime
- 2002-11-06 MX MXPA04004355A patent/MXPA04004355A/es active IP Right Grant
- 2002-11-06 PT PT02772624T patent/PT1446124E/pt unknown
- 2002-11-06 DE DE60213845T patent/DE60213845T2/de not_active Expired - Lifetime
- 2002-11-06 IL IL16174402A patent/IL161744A0/xx unknown
- 2002-11-06 AU AU2002337382A patent/AU2002337382B2/en not_active Ceased
- 2002-11-06 ES ES02772624T patent/ES2269769T3/es not_active Expired - Lifetime
- 2002-11-06 KR KR1020047007020A patent/KR100959607B1/ko not_active Expired - Fee Related
- 2002-11-06 BR BR0213906-5A patent/BR0213906A/pt not_active IP Right Cessation
- 2002-11-06 AT AT02772624T patent/ATE335488T1/de active
- 2002-11-06 DK DK02772624T patent/DK1446124T3/da active
- 2002-11-06 CN CNB028267958A patent/CN1298328C/zh not_active Expired - Fee Related
- 2002-11-06 CA CA2464758A patent/CA2464758C/en not_active Expired - Fee Related
- 2002-11-06 US US10/494,704 patent/US20050043395A1/en not_active Abandoned
- 2002-11-06 JP JP2003541842A patent/JP4694127B2/ja not_active Expired - Fee Related
- 2002-11-06 NZ NZ532525A patent/NZ532525A/en not_active IP Right Cessation
- 2002-11-08 AR ARP020104292A patent/AR037346A1/es not_active Application Discontinuation
-
2004
- 2004-05-03 IL IL161744A patent/IL161744A/en not_active IP Right Cessation
- 2004-05-06 ZA ZA200403455A patent/ZA200403455B/en unknown
- 2004-06-07 NO NO20042365A patent/NO328048B1/no not_active IP Right Cessation
-
2006
- 2006-11-09 CY CY20061101619T patent/CY1106259T1/el unknown
-
2011
- 2011-11-07 US US13/290,730 patent/US20120252827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL161744A0 (en) | 2005-11-20 |
| EP1446124B1 (en) | 2006-08-09 |
| NO20042365L (no) | 2004-06-07 |
| CN1298328C (zh) | 2007-02-07 |
| DE60213845D1 (de) | 2006-09-21 |
| WO2003039551A1 (en) | 2003-05-15 |
| JP2005511597A (ja) | 2005-04-28 |
| US20050043395A1 (en) | 2005-02-24 |
| DE60213845T2 (de) | 2007-03-29 |
| CA2464758C (en) | 2010-09-28 |
| JP4694127B2 (ja) | 2011-06-08 |
| GB0126879D0 (en) | 2002-01-02 |
| ATE335488T1 (de) | 2006-09-15 |
| CA2464758A1 (en) | 2003-05-15 |
| ZA200403455B (en) | 2005-08-29 |
| ES2269769T3 (es) | 2007-04-01 |
| NO328048B1 (no) | 2009-11-16 |
| PT1446124E (pt) | 2006-12-29 |
| HK1068546A1 (en) | 2005-04-29 |
| IL161744A (en) | 2012-01-31 |
| CN1612738A (zh) | 2005-05-04 |
| NZ532525A (en) | 2006-11-30 |
| KR100959607B1 (ko) | 2010-05-27 |
| CY1106259T1 (el) | 2011-06-08 |
| AU2002337382B2 (en) | 2008-06-12 |
| DK1446124T3 (da) | 2006-11-13 |
| KR20050043779A (ko) | 2005-05-11 |
| EP1446124A1 (en) | 2004-08-18 |
| AR037346A1 (es) | 2004-11-03 |
| US20120252827A1 (en) | 2012-10-04 |
| BR0213906A (pt) | 2004-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0223380D0 (en) | Combination therapy | |
| MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
| IL191796A0 (en) | Combination of zd6474 and pemetrexed | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
| MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
| IL191797A0 (en) | Combination of azd2171 and pemetrexed | |
| MX2007005356A (es) | Terapia de combinacion que comprende zd6474 y un antiadrogenico. | |
| GB0316127D0 (en) | Combination therapy | |
| GB0406446D0 (en) | Combination therapy | |
| GB0406445D0 (en) | Combination therapy | |
| IL172682A0 (en) | Combination therapy | |
| WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
| GB0223379D0 (en) | Combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |